Equity Profile

WST

West Pharmaceutical Services, Inc.

Health CareLife Sciences Tools & Services$22.8B

Jul23Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

West Pharmaceutical Services, Inc. (WST) operates in the healthcare sector, providing essential products and services for the life sciences industry....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to exceed $2.13

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and demand for its products.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

WST Q2-2026 Earnings Preview

Context

Company Snapshot

West Pharmaceutical Services, Inc. (WST) operates in the healthcare sector, providing essential products and services for the life sciences industry. The company specializes in developing and manufacturing components for drug delivery and packaging, making it a critical player in the ongoing healthcare advancements and pharmaceutical innovations.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+13.50%

Avg Stock Reaction

+0.61%

Last Quarter Recap

In Q1-2026, West Pharmaceutical Services reported an EPS of $2.13, surpassing expectations by 27%. The stock reacted positively, gaining 12.86% the following day.

Management Promises & Guidance

Continued focus on innovation in drug delivery systems.
Commitment to improving operational efficiencies.
Plans to expand into new markets.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a strong track record of beating EPS estimates, but revenue guidance remains unclear. Investors are looking for signs of sustained growth.

Bull Case

If West Pharmaceutical continues its trend of exceeding EPS estimates, it could signal strong operational performance and market demand, potentially leading to significant stock gains.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the recent volatility.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to exceed $2.13

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available

Revenue growth reflects the company's ability to expand its market presence and demand for its products.

Gross Margin

Not available

Gross margin indicates how efficiently the company is producing its products and managing costs.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong history of beating EPS estimates, this figure will be crucial in determining investor sentiment and stock movement.

What is the outlook for revenue growth in the upcoming quarters?

Investors will closely watch for any guidance on revenue growth, as it will indicate the company's ability to capitalize on market opportunities.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating West Pharmaceutical's ability to innovate and capture market share, especially given recent advancements in drug delivery technologies.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a higher expected move than historical averages, hinting at potential surprises.

Recent industry trends favor companies with innovative solutions, positioning West well.

Key Risk

If the EPS comes in below $2.00, it could challenge the prevailing positive sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether West Pharmaceutical can maintain its growth trajectory amidst industry challenges.

Bull Confirmed If

An EPS of $2.20 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $1.90 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±17.16%

Historical Avg

±14.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±17.2% while WST has averaged ±14.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

44.2%

Calls (10K)P/C Ratio: 0.93Puts (300)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If West Pharmaceutical beats expectations, history suggests a potential stock increase of around 2.75%, confirming strong operational performance.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience muted movement as investors reassess growth prospects.

Miss

Should the company miss expectations, history indicates a potential decline of about 14.40%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in drug delivery systems.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiencies.
4Guidance on revenue growth for the next quarter.
5Any strategic partnerships or collaborations that may impact future growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Domino's Pizza, Inc.

Company Snapshot

West Pharmaceutical Services, Inc. (WST) operates in the healthcare sector, providing essential products and services for the life sciences industry....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to exceed $2.13

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and demand for its products.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

WST Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+13.50%

Avg Stock Reaction

+0.61%

Last Quarter Recap

In Q1-2026, West Pharmaceutical Services reported an EPS of $2.13, surpassing expectations by 27%. The stock reacted positively, gaining 12.86% the following day.

Management Promises & Guidance

Continued focus on innovation in drug delivery systems.
Commitment to improving operational efficiencies.
Plans to expand into new markets.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a strong track record of beating EPS estimates, but revenue guidance remains unclear. Investors are looking for signs of sustained growth.

Bull Case

If West Pharmaceutical continues its trend of exceeding EPS estimates, it could signal strong operational performance and market demand, potentially leading to significant stock gains.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the recent volatility.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to exceed $2.13

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available

Revenue growth reflects the company's ability to expand its market presence and demand for its products.

Gross Margin

Not available

Gross margin indicates how efficiently the company is producing its products and managing costs.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong history of beating EPS estimates, this figure will be crucial in determining investor sentiment and stock movement.

What is the outlook for revenue growth in the upcoming quarters?

Investors will closely watch for any guidance on revenue growth, as it will indicate the company's ability to capitalize on market opportunities.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating West Pharmaceutical's ability to innovate and capture market share, especially given recent advancements in drug delivery technologies.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a higher expected move than historical averages, hinting at potential surprises.

Recent industry trends favor companies with innovative solutions, positioning West well.

Key Risk

If the EPS comes in below $2.00, it could challenge the prevailing positive sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether West Pharmaceutical can maintain its growth trajectory amidst industry challenges.

Bull Confirmed If

An EPS of $2.20 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $1.90 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±17.16%

Historical Avg

±14.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±17.2% while WST has averaged ±14.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

44.2%

Calls (10K)P/C Ratio: 0.93Puts (300)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If West Pharmaceutical beats expectations, history suggests a potential stock increase of around 2.75%, confirming strong operational performance.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience muted movement as investors reassess growth prospects.

Miss

Should the company miss expectations, history indicates a potential decline of about 14.40%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in drug delivery systems.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiencies.
4Guidance on revenue growth for the next quarter.
5Any strategic partnerships or collaborations that may impact future growth.